Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00919776Phase 2Completed

Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum

Role: collaborator

NCT00919451Phase 2Completed

Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy

Role: collaborator

NCT00919815Phase 2Completed

Ciclosporin in the Management of New Type 1 Reactions in Leprosy

Role: collaborator

NCT00919542Phase 2Completed

Ciclosporin in the Management of New Erythema Nodosum Leprosum

Role: collaborator

All 4 trials loaded